Center for the Study and Treatment of Castleman & Inflammatory Lymphadenopathies [CSTL]
The CSTL is a Program of Excellence of the Penn Orphan Disease Center.
The CSTL’s mission is to conduct groundbreaking research on Castleman Disease and other related lymphadenopathies to identify optimal treatments and provide world-class patient care.
The CSTL’s mission is to conduct groundbreaking translational research on Castleman Disease and related inflammatory lymphadenopathies to discover novel diagnostic biomarkers and therapeutics, identify optimal treatment approaches, and provide world-class patient care.
New Article Published on Journal of Clinical Investigation!
Thursday, July 11, 2019
A study recently published in the Journal of Clinical Investigation describes the treatment of three iMCD patients who previously did not respond to IL-6 blockers like siltuximab, the only FDA-approved drug for iMCD. These patients were treated with sirolimus, an mTOR inhibitor, and exhibited positive responses. These findings suggested that mTOR, a key pathway of the immune system, is a potential target in the treatment of IL-6 refractive iMCD. An ongoing clinical trial is taking the research further.
Check out the Penn News Release!
Study Spotlight: Insights from building a Castleman Disease-specific biospecimen bank
Wednesday, August 28, 2019
A study supported by the CDCN performed a detailed quantitative analysis of our international Contact Database and E-repository to find information that improves the collection and centralization of samples. One of the greatest challenges in advancing our understanding of rare diseases, such as Castleman disease, is the difficulty in collecting and centralizing both patient samples and relevant clinical data. These biospecimens and their information are crucial in conducting hypothesis-driven research that not only improves our understanding of the disease but also moves toward the goal of discovering new drugs and treatment regimens.